Skip to content

Prepaid expenses at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM

Other financials

Income statement

See full
Revenue$8.9M-2.9%
Gross profit$7.7M0.0%
Operating income-$8.4M-14.8%
Net income$1.5M+115%
EPS (diluted)$0.03+108%

Balance sheet

See full
Cash & equivalents$56.6M+324%
Total debt$33.1M+4.4%
Total equity$12.8M+137%
Total assets$71.0M+148%

Cash flow

See full
Operating cash flow-$6.5M-44.0%
CapEx$141.0K-81.3%
Free cash flow-$6.6M-26.0%

Valuation

See full
Market cap$279.45M+49.6%
Enterprise value$255.97M+33.6%
P/S6.2×+1.0×

Profitability

See full
Gross margin85.1%-0.5pp
Operating margin-62.4%-16.8pp
Net margin-60.9%-13.4pp
FCF margin-45.2%-16.8pp

Returns & leverage

See full
Return on equity253.3%
Debt / equity2.6×
Current ratio5.8×+3.6×

Where this comes from

Reported directly by TriSalus Life Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseCurrent.

The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about TriSalus Life Sciences, Inc.'s prepaid expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s prepaid expenses?
TriSalus Life Sciences, Inc. (TLSI) reported prepaid expenses of $2.59M in Q1 2026.
How has TriSalus Life Sciences, Inc.'s prepaid expenses changed year-over-year?
TriSalus Life Sciences, Inc.'s prepaid expenses increased by 4.5% year-over-year, from $2.48M to $2.59M.
What is the long-term trend for TriSalus Life Sciences, Inc.'s prepaid expenses?
Over 5 years (2020 to 2025), TriSalus Life Sciences, Inc.'s prepaid expenses has grown at a 26.4% compound annual growth rate (CAGR), from $673.2K to $2.17M.